Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy.
Breast. 2011 Oct;20 Suppl 3:S135-41. doi: 10.1016/S0960-9776(11)70311-3.
Chemotherapy is the only evidence based adjuvant systemic treatment option in triple negative breast cancer (TNBC). Despite emerging results for targeted biological therapies for this subpopulation, lack of robust results does not currently support their use beyond the confines of a clinical trial. Conventional systemic chemotherapy remains the standard of care and is curative in a minority of patients. There is no defined standard chemotherapy and there is currently no robust, prospective, randomized data to advise different use of specific chemotherapy agents in TNBC as compared to non-TNBC. Data suggest high sensitivity to chemotherapy, however it is yet to be determined whether this increased sensitivity is agent/regimen specific or whether it reflects general chemosensitivity. This review will focus on systemic chemotherapy in early TNBC, particularly anthracyclines and platinums, and potential predictive tools to guide chemotherapy use.
化疗是三阴性乳腺癌（TNBC）唯一有循证医学依据的辅助全身治疗选择。尽管针对这一亚群的靶向生物疗法有新的研究结果，但目前缺乏强有力的结果并不支持在临床试验之外使用这些药物。传统的全身化疗仍然是标准治疗方法，少数患者可以治愈。目前没有明确的标准化疗方案，也没有强有力的前瞻性随机数据来指导在 TNBC 中与非 TNBC 中使用特定化疗药物的不同用法。数据表明对化疗高度敏感，但尚不确定这种敏感性增加是药物/方案特异性的，还是反映了一般化疗敏感性。本综述将重点关注早期 TNBC 的全身化疗，特别是蒽环类药物和铂类药物，以及潜在的预测工具以指导化疗的应用。
